ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 969,47
0,88%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Olema Pharmaceuticals Inc (OLMA)

  7. Olema Pharmaceuticals Inc (OLMA) Actualités

OLMA Olema Pharmaceuticals Inc

9,48
-0,35 (-3,56%)
27 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Olema Pharmaceuticals Inc OLMA NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,35 -3,56% 9,48 01:13:09
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
9,87 9,51 10,09 9,95 9,83
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
08/4/202422:30GLOBEOlema Oncology to Participate in Canaccord Genuity 2024..
02/4/202422:29GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
11/3/202421:31EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/3/202421:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11/3/202421:05EDGAR2Form 8-K - Current report
11/3/202421:03GLOBEOlema Oncology Reports Fourth Quarter and Full-Year 2023..
06/3/202413:03GLOBEOlema Oncology Announces Publication of Data Highlighting..
04/3/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:30GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
29/2/202420:26EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:08EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202418:53EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202423:16EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
12/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
06/2/202413:01GLOBEOlema Oncology to Participate in Upcoming Investor..
05/2/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:30GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
01/2/202421:24EDGAR2Form 144 - Report of proposed sale of securities
31/1/202422:21EDGAR2Form S-3 - Registration statement under Securities Act of..
31/1/202420:58EDGAR2Form 144 - Report of proposed sale of securities
29/1/202413:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202415:07EDGAR2Form 8-K - Current report
08/1/202414:18EDGAR2Form 8-K - Current report
08/1/202414:12GLOBEOlema Oncology Nominates OP-3136, an Orally Bioavailable..
05/1/202423:26EDGAR2Form 8-K - Current report
05/1/202423:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/1/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202422:01GLOBEOlema Oncology to Present at 42nd Annual J.P. Morgan..
29/12/202321:54EDGAR2Form 144 - Report of proposed sale of securities
19/12/202300:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202323:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202302:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202302:30EDGAR2Form 3/A - Initial statement of beneficial ownership of..
06/12/202313:48EDGAR2Form 8-K - Current report
05/12/202323:15EDGAR2Form 8-K - Current report
05/12/202318:27GLOBEOlema Oncology Announces Palazestrant Demonstrates..
04/12/202322:29GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
01/12/202323:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202316:20EDGAR2Form 144 - Report of proposed sale of securities
28/11/202323:10GLOBEOlema Oncology to Present New Palazestrant Clinical Data in..
23/11/202301:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202301:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202301:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202301:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202321:25EDGAR2Form 144 - Report of proposed sale of securities
22/11/202321:04EDGAR2Form 144 - Report of proposed sale of securities

Dernières Valeurs Consultées

NASDAQ
OLMA
Olema Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés